iHapy

iHapy

Founded in 2015 and based in Shenzhen, iHapy operates as a private equity fund of funds manager focused on China's venture capital landscape. The firm's founding principals have maintained a deliberately low public profile, with no named executives in public record. iHapy deploys capital through a mix of primary fund commitments and direct secondary transactions, with a stated emphasis on late-stage and expansion-stage venture funds. iHapy's strategy spans fund-of-funds commitments, direct secondaries, and limited early-stage seed exposure. The portfolio tilts heavily toward information technology and healthcare — two sectors that have dominated Chinese venture dealmaking over the last decade. The firm participates across the venture lifecycle but concentrates its firepower on managers raising expansion or late-stage vehicles, where capital needs are larger and vintage diversification is harder to achieve. Geographic focus is exclusively China, consistent with the Shenzhen headquarters and the domestic character of its underlying fund relationships. The firm's scale remains opaque. No AUM figure, team size, or total deployment number has been publicly disclosed. iHapy does not maintain a LinkedIn presence and its website offers no executive biographies, portfolio manager names, or track-record data. The absence of disclosed principals is notable in a market where fund-of-funds relationships are heavily dependent on the credibility and network of the individuals placing the capital. What distinguishes iHapy structurally is the combination of a fund-of-funds mandate with a hands-on secondary desk. Most Chinese fund-of-funds operators act primarily as allocators to blind-pool vehicles; iHapy's concurrent activity in direct secondaries suggests a sourcing model that values visibility into existing portfolios — a posture more common among Western secondary specialists than among Shenzhen-based FoF managers. This dual approach gives the firm a potential structural edge in pricing GP-led continuation vehicles and LP-stake sales, though the lack of disclosed performance data makes it impossible to evaluate execution quality.